Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.84 |
| ▸ | TTR | P02766 | 1/20 | 0.84 |
| ▸ | ACHE | P22303 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18121772 | 0.91 | NPC1 (0.70) | NPC1TTRACHEKMT2A | |
| SCHEMBL18823571 | 0.89 | NPC1 (0.71) | NPC1TTRACHE | |
| SCHEMBL4860547 | 0.85 | NPC1 (0.67) | NPC1TTRACHE | |
| SCHEMBL4851995 | 0.80 | NPC1 (0.60) | NPC1TTRACHE | |
| SCHEMBL4860249 | 0.80 | NPC1 (0.59) | NPC1TTRACHE | |
| SCHEMBL6743887 | 0.80 | NPC1 (0.66) | NPC1TTRACHEKMT2A | |
| SCHEMBL4855388 | 0.79 | NPC1 (0.76) | NPC1TTRACHE | |
| SCHEMBL4853290 | 0.78 | NPC1 (0.56) | NPC1TTRACHE | |
| SCHEMBL14301290 | 0.77 | NPC1 (0.75) | NPC1TTRACHEKMT2A | |
| SCHEMBL4861818 | 0.77 | NPC1 (0.55) | NPC1TTRACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3372600-B1 | FUSED HETEROCYCLIC COMPOUND DERIVATIVE AND APPLICATION THEREOF | NHWA PHARMA CORP (CN) | 2021-09-08 | — | — | EP | disclosed |
| WO-2017071576-A1 | FUSED HETEROCYCLIC COMPOUND DERIVATIVE AND APPLICATION THEREOF | 江苏恩华药业股份有限公司 | 2017-05-04 | — | — | WO | disclosed |
| US-20040138230-A1 | Heterocyclic substituted piperazines for the treatment of schizophrenia | ANDREANA TONJA LYNN (US) | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138230-A1 | Heterocyclic substituted piperazines for the treatment of schizophrenia | CNR1, DRD2, CNR2 | NPC1 2509/4885TTR 4604/4885ACHE 805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.